Hwail Pharmaceutical Co.,Ltd.

KOSDAQ:A061250 Stock Report

Market Cap: ₩105.3b

Hwail PharmaceuticalLtd Past Earnings Performance

Past criteria checks 0/6

There is insufficient data on Hwail PharmaceuticalLtd's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update31 Mar 2017

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Hwail PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A061250 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 17107,8751,92510,963392
31 Dec 16111,5196,38211,445391
30 Sep 16115,20511,4329,097396
30 Jun 16116,60711,2508,439394
31 Mar 16113,36510,0457,423405
31 Dec 15106,1305,4536,555430
30 Sep 15105,4053,4227,370456
30 Jun 1599,3273,7677,537512
31 Mar 1596,5503,8187,747552
31 Dec 1496,1034,1328,109565
30 Sep 1490,6403,4058,461596
30 Jun 1489,3763,1418,703636
31 Mar 1493,1623,5778,810636

Quality Earnings: Insufficient data to determine if A061250 has high quality earnings.

Growing Profit Margin: Insufficient data to determine if A061250's profit margins have improved over the past year.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if A061250's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare A061250's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if A061250's earnings growth over the past year exceeded the Pharmaceuticals industry average.


Return on Equity

High ROE: A061250 has a negative Return on Equity (0%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/19 11:36
End of Day Share Price 2025/01/17 00:00
Earnings2017/03/31
Annual Earnings2016/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hwail Pharmaceutical Co.,Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
JooYong KimBookook Securities Co. Ltd
Kidal BaeShinhan Investment Corp.